University of Cambridge
Dr. David Bulmer
Dr Bulmer has unique insight into the development of novel therapeutic approaches targeting nociceptors for the treatment of visceral pain in IBD and IBS, having established research labs within industry (GlaxoSmithKline) and academia (QMUL, University of Cambridge). His work is at the forefront of translational studies on visceral pain examining human visceral afferent activity and working extensively with colonic biopsy samples from patients with gastrointestinal disease.
Wednesday, September 21, 2022
|4:30pm EDT–6:00pm EDT|
Contribution of Itch, Inflammation, and the Microbiota to Colorectal Nociception: Opportunities for Therapeutic Intervention?
Categories: Topical Workshop
Presented By: Dr. Nathalie Vergnolle, Prof. Stuart Brierley, Dr. David Bulmer
Room: 713 A
Visceral pain is a leading cause of morbidity for individuals suffering from gastrointestinal (GI) diseases. For many people the principal…
Send me my favorite sessions: